At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Tralokinumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Ph 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults With Asthma Inadequately Controlled on Inhaled Corticosteroid (MESOS)
In Brief
A Phase 2 clinical trial evaluating Tralokinumab and Placebo for Asthma. Completed, enrolled 79 participants across 15 sites in 3 countries.
Detailed Summary
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Controlled on Inhaled Corticosteroid.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada, Denmark, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartSep 2015
Primary CompletionJun 2017
TodayJul 2026
First PostedMay 20, 2015
Enrollment StartSep 29, 2015
Primary CompletionJun 21, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.1 years ago
Interventions
Tralokinumabbiological
Subcutaneous Injection
Placeboother
Subcutaneous Injection